Altimmune Inc (NASDAQ: ALT)’s stock price has soared by 4.07 in relation to previous closing price of 8.57. Nevertheless, the company has seen a gain of 19.40% in its stock price over the last five trading days. globenewswire.com reported 2024-11-26 that GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1×1 meetings at the following investor conferences:
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
The 36-month beta value for ALT is at 0.13. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALT is 70.53M, and currently, shorts hold a 32.52% of that float. The average trading volume for ALT on November 26, 2024 was 2.72M shares.
ALT’s Market Performance
The stock of Altimmune Inc (ALT) has seen a 19.40% increase in the past week, with a 27.23% rise in the past month, and a 37.64% gain in the past quarter. The volatility ratio for the week is 9.65%, and the volatility levels for the past 30 days are at 10.65% for ALT. The simple moving average for the past 20 days is 14.21% for ALT’s stock, with a 17.95% simple moving average for the past 200 days.
Analysts’ Opinion of ALT
Many brokerage firms have already submitted their reports for ALT stocks, with UBS repeating the rating for ALT by listing it as a “Buy.” The predicted price for ALT in the upcoming period, according to UBS is $26 based on the research report published on November 12, 2024 of the current year 2024.
Goldman gave a rating of “Neutral” to ALT, setting the target price at $13 in the report published on January 24th of the current year.
ALT Trading at 24.68% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.90% of loss for the given period.
Volatility was left at 10.65%, however, over the last 30 days, the volatility rate increased by 9.65%, as shares surge +20.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.57% upper at present.
During the last 5 trading sessions, ALT rose by +19.14%, which changed the moving average for the period of 200-days by -14.42% in comparison to the 20-day moving average, which settled at $7.81. In addition, Altimmune Inc saw -20.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Drutz David, who sale 16,011 shares at the price of $6.90 back on Aug 19 ’24. After this action, Drutz David now owns 41,958 shares of Altimmune Inc, valued at $110,547 using the latest closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -1913.65 for the present operating margin
- -38.58 for the gross margin
The net margin for Altimmune Inc stands at -1990.77. The total capital return value is set at -0.71. Equity return is now at value -72.96, with -65.84 for asset returns.
Currently, EBITDA for the company is -87.94 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 11471.45. The receivables turnover for the company is 0.12for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.87.
Conclusion
In conclusion, Altimmune Inc (ALT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
